Not Signed In -
Waardenburg Syndrome |
|
|
Clinical Trial: Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
This study is currently recruiting patients.
|
Purpose
This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs and symptoms of Hypereosinophilic Syndrome.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Hypereosinophilic Syndrome Hypereosinophilia | Drug: mepolizumab | Phase III |
MedlinePlus related topics: Blood and Blood Disorders
Study Type: Interventional
Study Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion criteria:
- Participation in study 100185
- Not pregnant or nursing
Exclusion criteria:
- Significantly abnormal laboratory values
- Abnormal cardiac function - angina, myocardial infarction
- Pregnancy
Location and Contact Information
California
San Diego, California, 92103, United States; Not yet recruiting
Colorado
Denver, Colorado, 80206, United States; Not yet recruiting
Maryland
Bethesda, Maryland, 20892, United States; Recruiting
Massachusetts
Boston, Massachusetts, 02215, United States; Not yet recruiting
Minnesota
Rochester, Minnesota, 55905, United States; Not yet recruiting
Ohio
Cincinnati, Ohio, 45229, United States; Not yet recruiting
Tennessee
Nashville, Tennessee, 37203, United States; Not yet recruiting
Utah
Salt Lake City, Utah, 84132, United States; Not yet recruiting
Virginia
Richmond, Virginia, 23298, United States; Not yet recruiting
Wisconsin
Madison, Wisconsin, 53792, United States; Not yet recruiting
Canada, Alberta
Edmonton, Alberta, T6G 1Z2, Canada; Not yet recruiting
Canada, Manitoba
Winnipeg, Manitoba, R3C 0N2, Canada; Not yet recruiting
Canada, Nova Scotia
Halifax, Nova Scotia, B3H 1V7, Canada; Not yet recruiting
Canada, Ontario
Hamilton, Ontario, L8N 3Z5, Canada; Not yet recruiting
Toronto, Ontario, M5T 3A9, Canada; Recruiting
Canada, Quebec
Montreal, Quebec, H3A 1A1, Canada; Not yet recruiting
More Information
Record last reviewed: November 2004
Last Updated: November 29, 2004
Record first received: November 22, 2004
ClinicalTrials.gov Identifier: NCT00097370
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
